Zoetis Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
$ZTS
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
| FORM | |||||
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): May 20, 2024
| (Exact name of registrant as specified in its charter) | ||
| (State or other jurisdiction | (Commission File | (I.R.S. Employer | ||||||||||||
| of incorporation) | Number) | Identification No.) | ||||||||||||
| (Address of principal executive offices) | (Zip Code) | |||||||||||||
(973 ) 822-7000
| (Registrant's telephone number, including area code) | ||
| Not Applicable | ||
| (Former Name or Former Address, if changed since last report) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 20, 2024, in connection with Heidi C. Chen’s previously announced separation, Zoetis Inc. (the “Company”) entered into a Letter Agreement (the “Letter Agreement”) with Ms. Chen. The Letter Agreement provides that Ms. Chen will continue employment as a non-corporate officer employee of the Company through July 16, 2024 (the “Termination Date”), and through the Termination Date will continue receiving her current annual base salary and employment benefits. After the Termination Date Ms. Chen will serve as a non-employee consultant through December 31, 2024, and in exchange for such advisory services, and subject to compliance with the terms of the Letter Agreement and the execution of a release agreement, Ms. Chen will receive a consulting fee of $350,000. Ms. Chen will also be eligible to receive severance payments and benefits in accordance with the terms of the Zoetis Executive Severance Plan and as set forth in the Letter Agreement.
The foregoing description of the Letter Agreement is qualified in its entirety by reference to the full text of the Letter Agreement, which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
| Exhibit No. | Description | ||||
| Letter Agreement | |||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ZOETIS INC. | ||||||||
| Dated: May 24, 2024 | By: | /s/ Roxanne Lagano | ||||||
| Roxanne Lagano | ||||||||
| Executive Vice President, | ||||||||
| General Counsel & Secretary | ||||||||